Recent

% | $
Quotes you view appear here for quick access.

Exact Sciences Corporation Message Board

  • lwright36 lwright36 Dec 18, 2012 10:17 PM Flag

    Room to Run

    Been doing significant due diligence, in fact re-analyzing to make sure. Bought in today. Large block
    Buying more tomorrow, Hard to narrow in on market value, but thinking should be $20 stock for sure. But upside makes more attractive. IMO, not going down over next few months. Good luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • @Citidel, Rann asked for "stocks" in similar circumstances, Biotechs, waiting for FDA approval, market caps, potential earnings etc. Based solely on those "charting" criteria EXAS is a "comp"

    • The cost to treat colon cancer is $14 billion annually and this test should all but eradicate this preventable disease. Government statistical nerds who perform the cost-benefit analysis will love it. Only test of its kind that finds precancers , great patents, some of them only recently issued and the CEO is a patent attorney. Huge market here and worldwide.

    • You are correct. I also expect a double in 2013. The cost to treat colon cancer is $14 billion annually and this test should all but eradicate this preventable disease. Government statistical nerds who perform the cost-benefit analysis will love it. Only test of its kind that finds precancers, great patents, some of them only recently issued and the CEO is a patent attorney. Huge market here and worldwide.

      Sentiment: Strong Buy

    • You are correct; I also expect a double in 2013. The cost to treat colon cancer is $14 billion annually and this test should all but eradicate this preventable disease. Government statistical nerds who perform the cost-benefit analysis will love it. Only test of its kind that finds precancers , great patents, some of them only recently issued and the CEO is a patent attorney. Huge market here and worldwide.

      Sentiment: Strong Buy

    • You are correct, I also expect a double in 2013. The cost to treat colon cancer is $14 billion annually and this test should all but eradicate this preventable disease. Government statistical nerds who perform the cost-benefit analysis will love it. Only test of its kind that finds precancers , great patents, some of them only recently issued and the CEO is a patent attorney. Huge market here and worldwide.

    • You are correct; I also expect a double in 2013. The cost to treat colon cancer is $14 billion annually and this test should all but eradicate this preventable disease. Government statistical nerds who perform the cost-benefit analysis will love it. Only test of it's kind that finds precancers - great patents, some of them only recently issued, and the CEO is a patent attorney. Huge market here and worldwide.

    • You are correct, I also expect a double in 2013. The cost to treat colon cancer is $14 billion annually and this test should all but eradicate this preventable disease. Government statistical nerds who perform the cost-benefit analysis will love it. Only test of it's kind that finds precancers - great patents, some of them only recently issued, and the CEO is a patent attorney. Huge market here and worldwide.

    • You are correct. I also see a double in 2013. This test will significantly reduce the $14 billion in health care costs related to colon cancer and should all but eradicate this preventable disease. Government statistical nerds that analyze cost-benefit will love it. Only test in the market that identifies precancers plus great patents and the CEO is a patent attorney. Huge market here and worldwide.

    • Thanks for your post lwright,
      But please explain a little on your methods? How is it that you come about your $20 target. And is this your target prior to or after test results. If you are placing a value on future events, they of course, you must apply the same meteric as you would to other biotech stocks with a potential market the same size as the potential market here AND of course, the probability for success needs to be at least similar. Lastly, my criteria requires a comparison to market cap of 3 or more such stocks for a "comp value". With a market cap of 675 Million, don't you think EXAS is already fully valued when placed side by side with companies in similar circumstances? $20 would put the market cap at 1 Billion, 1 Hundred and Sixteen MILLION dollars. That's one hell of a lot of dough for a loaf of bread that has yet to be put in the oven, don't ya think? I have great expectations for this stock once results are conclusive, but at $20 prior to results, I would be inclined to see that future success as already "baked in". Ive got to agree with the poster, Crapneb, the main incentive here is the chart formation. Perhaps you can enlighten me otherwise?

 
EXAS
11.25-0.04(-0.35%)9:30 AMEDT